Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.16
JNJ's Cash to Debt is ranked higher than
74% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. JNJ: 2.16 )
JNJ' s 10-Year Cash to Debt Range
Min: 0.17   Max: 6.28
Current: 2.16

0.17
6.28
Equity to Asset 0.58
JNJ's Equity to Asset is ranked higher than
67% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. JNJ: 0.58 )
JNJ' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.67
Current: 0.58

0.46
0.67
Interest Coverage 38.13
JNJ's Interest Coverage is ranked higher than
64% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.95 vs. JNJ: 38.13 )
JNJ' s 10-Year Interest Coverage Range
Min: 19.77   Max: 230.91
Current: 38.13

19.77
230.91
F-Score: 7
Z-Score: 5.73
M-Score: -2.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.09
JNJ's Operating margin (%) is ranked higher than
96% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.59 vs. JNJ: 28.09 )
JNJ' s 10-Year Operating margin (%) Range
Min: 17.84   Max: 26.92
Current: 28.09

17.84
26.92
Net-margin (%) 23.27
JNJ's Net-margin (%) is ranked higher than
95% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.31 vs. JNJ: 23.27 )
JNJ' s 10-Year Net-margin (%) Range
Min: 12.52   Max: 21.65
Current: 23.27

12.52
21.65
ROE (%) 23.09
JNJ's ROE (%) is ranked higher than
95% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. JNJ: 23.09 )
JNJ' s 10-Year ROE (%) Range
Min: 17.02   Max: 30.17
Current: 23.09

17.02
30.17
ROA (%) 13.12
JNJ's ROA (%) is ranked higher than
94% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. JNJ: 13.12 )
JNJ' s 10-Year ROA (%) Range
Min: 8.93   Max: 17.94
Current: 13.12

8.93
17.94
ROC (Joel Greenblatt) (%) 90.28
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.17 vs. JNJ: 90.28 )
JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 51.96   Max: 110.98
Current: 90.28

51.96
110.98
Revenue Growth (%) 3.90
JNJ's Revenue Growth (%) is ranked higher than
69% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. JNJ: 3.90 )
JNJ' s 10-Year Revenue Growth (%) Range
Min: 1.4   Max: 14.6
Current: 3.9

1.4
14.6
EBITDA Growth (%) -1.50
JNJ's EBITDA Growth (%) is ranked higher than
65% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. JNJ: -1.50 )
JNJ' s 10-Year EBITDA Growth (%) Range
Min: -6.6   Max: 16
Current: -1.5

-6.6
16
EPS Growth (%) 0.20
JNJ's EPS Growth (%) is ranked higher than
70% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. JNJ: 0.20 )
JNJ' s 10-Year EPS Growth (%) Range
Min: -8.6   Max: 18
Current: 0.2

-8.6
18
» JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

JNJ Guru Trades in Q4 2013

Ray Dalio 113,193 sh (+314.73%)
Paul Tudor Jones 26,088 sh (+267.44%)
John Rogers 349,157 sh (+173.69%)
Stanley Druckenmiller 235,000 sh (+82.17%)
Jim Simons 5,498,400 sh (+67.87%)
Steven Cohen 224,813 sh (+48.76%)
Sarah Ketterer 559,450 sh (+31.25%)
Murray Stahl 32,614 sh (+4.49%)
Pioneer Investments 4,013,743 sh (+3.45%)
Richard Pzena 866,458 sh (+2.21%)
James Barrow 17,330,009 sh (+0.79%)
Chris Davis 164,755 sh (+0.77%)
Jean-Marie Eveillard 1,607,280 sh (+0.67%)
Mario Gabelli 411,797 sh (+0.58%)
Bill Frels 1,821,701 sh (+0.35%)
First Pacific Advisors 1,501,800 sh (+0.23%)
Ken Fisher 10,165,567 sh (+0.21%)
Tweedy Browne Global Value 865,835 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Richard Snow 3,235 sh (unchged)
Steven Romick 1,425,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Michael Price 35,000 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Tom Gayner 580,600 sh (-0.03%)
Donald Yacktman 9,610,642 sh (-0.09%)
Jeff Auxier 97,452 sh (-0.13%)
Dodge & Cox 38,625 sh (-0.26%)
Mark Hillman 30,746 sh (-0.27%)
Tweedy Browne 4,305,931 sh (-0.42%)
Manning & Napier Advisors, Inc 4,132,692 sh (-0.49%)
Ruane Cunniff 74,094 sh (-0.54%)
PRIMECAP Management 13,689,047 sh (-0.9%)
Robert Olstein 91,000 sh (-1.09%)
Jeremy Grantham 19,775,624 sh (-6.76%)
HOTCHKIS & WILEY 3,819,961 sh (-7.62%)
Richard Perry 342,277 sh (-11.99%)
Chuck Royce 11,300 sh (-16.3%)
John Hussman 102,650 sh (-49.35%)
Prem Watsa 84,700 sh (-97.12%)
» More
Q1 2014

JNJ Guru Trades in Q1 2014

George Soros 102,500 sh (New)
RS Investment Management 7,228 sh (New)
Joel Greenblatt 7,496 sh (New)
John Buckingham 45,697 sh (New)
Ray Dalio 262,993 sh (+132.34%)
First Pacific Advisors 1,936,200 sh (+28.93%)
Steven Romick 1,835,000 sh (+28.77%)
Sarah Ketterer 696,350 sh (+24.47%)
Robert Olstein 110,000 sh (+20.88%)
Manning & Napier Advisors, Inc 4,727,195 sh (+14.39%)
Bill Frels 2,011,442 sh (+10.42%)
John Rogers 366,918 sh (+5.09%)
HOTCHKIS & WILEY 3,932,985 sh (+2.96%)
Ruane Cunniff 75,794 sh (+2.29%)
Jean-Marie Eveillard 1,617,567 sh (+0.64%)
Richard Snow 3,245 sh (+0.31%)
Richard Pzena 868,139 sh (+0.19%)
Michael Price 35,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Prem Watsa 84,700 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Richard Perry 342,277 sh (unchged)
Dodge & Cox 38,625 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Stanley Druckenmiller Sold Out
Chris Davis Sold Out
Jeff Auxier 97,237 sh (-0.22%)
Donald Yacktman 9,572,850 sh (-0.39%)
Tweedy Browne 4,269,206 sh (-0.85%)
Murray Stahl 32,329 sh (-0.87%)
Tom Gayner 574,200 sh (-1.1%)
Ken Fisher 9,977,824 sh (-1.85%)
James Barrow 16,953,029 sh (-2.18%)
Pioneer Investments 3,891,373 sh (-3.05%)
Mario Gabelli 395,061 sh (-4.06%)
PRIMECAP Management 12,300,986 sh (-10.14%)
Jeremy Grantham 17,574,048 sh (-11.13%)
Chuck Royce 7,300 sh (-35.4%)
Jim Simons 2,659,200 sh (-51.64%)
Paul Tudor Jones 4,000 sh (-84.67%)
Steven Cohen 9,821 sh (-95.63%)
John Hussman 2,650 sh (-97.42%)
» More
Q2 2014

JNJ Guru Trades in Q2 2014

Paul Tudor Jones 5,700 sh (+42.5%)
John Rogers 522,727 sh (+42.46%)
Richard Pzena 1,155,666 sh (+33.12%)
Sarah Ketterer 837,250 sh (+20.23%)
Jim Simons 3,145,500 sh (+18.29%)
Pioneer Investments 4,329,534 sh (+11.26%)
RS Investment Management 7,928 sh (+9.68%)
Ken Fisher 10,448,448 sh (+4.72%)
John Buckingham 46,512 sh (+1.78%)
Manning & Napier Advisors, Inc 4,769,286 sh (+0.89%)
James Barrow 17,065,230 sh (+0.66%)
Jean-Marie Eveillard 1,623,482 sh (+0.37%)
Ruane Cunniff 76,012 sh (+0.29%)
Tweedy Browne Global Value 865,835 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Caxton Associates 100,000 sh (unchged)
Michael Price 35,000 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Prem Watsa 84,700 sh (unchged)
Richard Perry 342,277 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Dodge & Cox 38,625 sh (unchged)
Richard Snow 3,245 sh (unchged)
Chuck Royce Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 12,242,420 sh (-0.48%)
Bill Frels 1,996,199 sh (-0.76%)
Tweedy Browne 4,196,224 sh (-1.71%)
Murray Stahl 31,683 sh (-2%)
Jeff Auxier 94,101 sh (-3.23%)
First Pacific Advisors 1,851,700 sh (-4.36%)
Steven Romick 1,750,000 sh (-4.63%)
Donald Yacktman 9,045,902 sh (-5.5%)
Mario Gabelli 373,186 sh (-5.54%)
Yacktman Focused Fund 3,300,000 sh (-13.16%)
Jeremy Grantham 14,297,233 sh (-18.65%)
Robert Olstein 87,000 sh (-20.91%)
John Hussman 1,325 sh (-50%)
George Soros 50,000 sh (-51.22%)
HOTCHKIS & WILEY 1,426,614 sh (-63.73%)
Ray Dalio 65,893 sh (-74.94%)
» More
Q3 2014

JNJ Guru Trades in Q3 2014

Joel Greenblatt 14,319 sh (New)
Paul Tudor Jones 17,426 sh (+205.72%)
Ray Dalio 84,193 sh (+27.77%)
Dodge & Cox 47,095 sh (+21.93%)
John Buckingham 47,934 sh (+3.06%)
John Rogers 536,616 sh (+2.66%)
Richard Pzena 1,184,416 sh (+2.49%)
Sarah Ketterer 853,150 sh (+1.9%)
Jean-Marie Eveillard 1,651,622 sh (+1.73%)
Richard Snow 3,270 sh (+0.77%)
Ruane Cunniff 76,259 sh (+0.32%)
John Hussman 1,325 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Richard Perry 342,277 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
RS Investment Management 7,928 sh (unchged)
Michael Price 35,000 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
George Soros Sold Out
Ken Fisher 10,446,156 sh (-0.02%)
PRIMECAP Management 12,217,813 sh (-0.2%)
Jeff Auxier 93,726 sh (-0.4%)
Bill Frels 1,987,137 sh (-0.45%)
Tweedy Browne 4,163,934 sh (-0.77%)
Murray Stahl 31,318 sh (-1.15%)
Mario Gabelli 366,366 sh (-1.83%)
Prem Watsa 82,850 sh (-2.18%)
Yacktman Fund 3,900,000 sh (-3.7%)
Donald Yacktman 8,651,258 sh (-4.36%)
Robert Olstein 83,000 sh (-4.6%)
Yacktman Focused Fund 3,100,000 sh (-6.06%)
Pioneer Investments 3,972,255 sh (-8.25%)
James Barrow 15,350,650 sh (-10.05%)
Jeremy Grantham 12,140,495 sh (-15.09%)
Jim Simons 2,643,000 sh (-15.98%)
First Pacific Advisors 1,473,500 sh (-20.42%)
Steven Romick 1,385,000 sh (-20.86%)
Manning & Napier Advisors, Inc 2,409,406 sh (-49.48%)
HOTCHKIS & WILEY 2,862 sh (-99.8%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2014-09-30 Reduce -99.8%0.53%$99.82 - $108.64 $ 108.254%2862
James Barrow 2014-09-30 Reduce -10.05%0.24%$99.82 - $108.64 $ 108.254%15350650
Yacktman Focused Fund 2014-09-30 Reduce -6.06%0.21%$99.82 - $108.64 $ 108.254%3100000
Donald Yacktman 2014-09-30 Reduce -4.36%0.17%$99.82 - $108.64 $ 108.254%8651258
Yacktman Fund 2014-09-30 Reduce -3.7%0.13%$99.82 - $108.64 $ 108.254%3900000
George Soros 2014-09-30 Sold Out 0.04%$99.82 - $108.64 $ 108.254%0
Ray Dalio 2014-09-30 Add 27.77%0.02%$99.82 - $108.64 $ 108.254%84193
Joel Greenblatt 2014-09-30 New Buy0.02%$99.82 - $108.64 $ 108.254%14319
Dodge & Cox 2014-09-30 Add 21.93%$99.82 - $108.64 $ 108.254%47095
HOTCHKIS & WILEY 2014-06-30 Reduce -63.73%0.89%$96.54 - $105.76 $ 108.257%1426614
Yacktman Focused Fund 2014-06-30 Reduce -13.16%0.51%$96.54 - $105.76 $ 108.257%3300000
Robert Olstein 2014-06-30 Reduce -20.91%0.31%$96.54 - $105.76 $ 108.257%87000
Donald Yacktman 2014-06-30 Reduce -5.5%0.21%$96.54 - $105.76 $ 108.257%9045902
John Rogers 2014-06-30 Add 42.46%0.2%$96.54 - $105.76 $ 108.257%522727
Tweedy Browne 2014-06-30 Reduce -1.71%0.17%$96.54 - $105.76 $ 108.257%4196224
Richard Pzena 2014-06-30 Add 33.12%0.17%$96.54 - $105.76 $ 108.257%1155666
Ray Dalio 2014-06-30 Reduce -74.94%0.16%$96.54 - $105.76 $ 108.257%65893
George Soros 2014-06-30 Reduce -51.22%0.05%$96.54 - $105.76 $ 108.257%50000
John Hussman 2014-06-30 Reduce -50%0.01%$96.54 - $105.76 $ 108.257%1325
Joel Greenblatt 2014-06-30 Sold Out 0.01%$96.54 - $105.76 $ 108.257%0
John Hussman 2014-03-31 Reduce -97.42%0.65%$86.62 - $97.44 $ 108.2517%2650
Robert Olstein 2014-03-31 Add 20.88%0.26%$86.62 - $97.44 $ 108.2517%110000
PRIMECAP Management 2014-03-31 Reduce -10.14%0.15%$86.62 - $97.44 $ 108.2517%12300986
Ray Dalio 2014-03-31 Add 132.34%0.12%$86.62 - $97.44 $ 108.2517%262993
George Soros 2014-03-31 New Buy0.1%$86.62 - $97.44 $ 108.2517%102500
Chris Davis 2014-03-31 Sold Out 0.04%$86.62 - $97.44 $ 108.2517%0
Joel Greenblatt 2014-03-31 New Buy0.01%$86.62 - $97.44 $ 108.2517%7496
Prem Watsa 2013-12-31 Reduce -97.12%15.54%$85.61 - $95.63 $ 108.2517%84700
George Soros 2013-12-31 Sold Out 1.2%$85.61 - $95.63 $ 108.2517%0
Vanguard Health Care Fund 2013-12-31 Sold Out 0.85%$85.61 - $95.63 $ 108.2517%0
John Hussman 2013-12-31 Reduce -49.35%0.48%$85.61 - $95.63 $ 108.2517%102650
John Rogers 2013-12-31 Add 173.69%0.25%$85.61 - $95.63 $ 108.2517%349157
HOTCHKIS & WILEY 2013-12-31 Reduce -7.62%0.12%$85.61 - $95.63 $ 108.2517%3819961
Joel Greenblatt 2013-12-31 Sold Out 0.09%$85.61 - $95.63 $ 108.2517%0
Ray Dalio 2013-12-31 Add 314.73%0.06%$85.61 - $95.63 $ 108.2517%113193
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Johnson & Johnson

Bill Frels Comments on Johnson & Johnson - Oct 20, 2014

Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

John Rogers' Ariel Fund Comments on Johnson & Johnson - Feb 28, 2014

Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled...

After its slide in the current century, Johnson & Johnson took the opportunity to reinvigorate itself. Alex Gorsky, who became CEO in 2012, led a major transformation; he charged his new operations head, Sandra Peterson, with structural improvements across the company. On the pharmaceutical side, it refocused its Research & Development (R&D) on blockbuster segments such as anti-coagulants and oncology. In its medical technology division, the company boldly exited the underperforming drug-eluding stent business and deployed foreign cash through the acquisition of high-margin specialty implant maker Synthes, a Swiss company. Johnson & Johnson even bolstered its consumer brands such as Neutrogena and Band-Aid, which offer lower margins but steady cash flows. More importantly, it has gotten past the embarrassing 2010 recalls of the children's versions of Tylenol, Motrin, Zyrtec and Benadryl, and all four are now back on the shelves. We always look forward, even when analyzing a 127-year old company, and at this point see a lean, mean heavyweight ready to compete.

From John Rogers (Trades, Portfolio)' Ariel International Fund & Ariel Global Fund fourth quarter 2013 commentary by Rupal J. Bhansali.

Check out latest stock trades

Top Ranked Articles about Johnson & Johnson

Guru Ken Fisher’s Top Five Quarterly Stocks
CEO and CIO of Fisher Investments, Ken Fisher, had a pretty busy third quarter. Fisher purchased a total of 47 new stocks. His third quarter portfolio holds 5454 stocks and is valued at over $46.911 billion. The following five stocks represent the five companies where Fisher holds the largest stake in. Read more...
Bill Frels Comments on Johnson & Johnson
Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017. Read more...
Top Five Mega-Cap Stocks That Gurus Like
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mega cap companies which are held by the most gurus. The following five mega-capped companies are held by the largest number of gurus during the past quarter. Read more...
Money Managers Tweedy Browne Report Largest Stocks, Topped by Johnson & Johnson
Tweedy Browne (Trades, Portfolio) is a 93-year-old fund which focuses on undervalued securities, and which gained its investment approach from the late Benjamin Graham. The fund is owned and managed by William Browne, Thomas Shrager, John Spears and Robert Wyckoff, Jr. Read more...
Investor Steven Romick's Top 5 Increases of First Quarter
FPA Crescent Fund’s Steven Romick (Trades, Portfolio) in the first quarter preferred to have cash ready to put to work in case volatility hit the markets, rather than buy new stocks. He believes a period of volatility – and the low-priced opportunities it would bring with it – could occur soon. Read more...
Gurus’ Most-Sold Fourth Quarter Stocks - Each at a 10-Year High
In the fourth quarter of 2013, the S&P 500 hit record highs, while the majority of corporations (95) reported negative EPS guidance, and 12 issued positive EPS guidance, according to FactSet Research. The estimated earnings growth rate for all corporations for the quarter was estimated to be 6.3%, according to FactSet. The Financial sector led growth, increasing earnings by 24.2%. Energy lagged all sectors, with an 8% decline in earnings. Read more...
Weekly 52-Week Highs Highlight: MAR, JNJ, HAL, BHI
According to GuruFocus list of 52-week highs; Marriott International Inc., Johnson & Johnson, Halliburton Company and Baker Hughes Inc. have all reached their 52-week highs. Read more...
Top Owned Health Care Stocks of the Fourth Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the fourth quarter, the following five health care companies are held by the largest number of gurus. Read more...
John Rogers' Ariel Fund Comments on Johnson & Johnson
Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled... Read more...
Money Managers Tweedy Browne Report New Stocks, Topped by Johnson & Johnson
Tweedy Browne (Trades, Portfolio) is a 93-year-old fund which focuses on undervalued securities, and which gained its investment approach from the late Benjamin Graham. The fund is owned and managed by William Browne, Thomas Shrager, John Spears and Robert Wyckoff, Jr. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.90
JNJ's P/E(ttm) is ranked higher than
92% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.00 vs. JNJ: 17.90 )
JNJ' s 10-Year P/E(ttm) Range
Min: 10.5   Max: 23.97
Current: 17.9

10.5
23.97
P/B 4.00
JNJ's P/B is ranked higher than
68% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. JNJ: 4.00 )
JNJ' s 10-Year P/B Range
Min: 2.68   Max: 6.21
Current: 4

2.68
6.21
P/S 4.20
JNJ's P/S is ranked higher than
71% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.96 vs. JNJ: 4.20 )
JNJ' s 10-Year P/S Range
Min: 2.16   Max: 4.29
Current: 4.2

2.16
4.29
PFCF 21.30
JNJ's PFCF is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. JNJ: 21.30 )
JNJ' s 10-Year PFCF Range
Min: 10.29   Max: 24.69
Current: 21.3

10.29
24.69
EV-to-EBIT 13.65
JNJ's EV-to-EBIT is ranked higher than
91% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. JNJ: 13.65 )
JNJ' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 15.8
Current: 13.65

8.4
15.8
Shiller P/E 22.70
JNJ's Shiller P/E is ranked higher than
90% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.40 vs. JNJ: 22.70 )
JNJ' s 10-Year Shiller P/E Range
Min: 12.9   Max: 30.69
Current: 22.7

12.9
30.69
Current Ratio 2.61
JNJ's Current Ratio is ranked higher than
73% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. JNJ: 2.61 )
JNJ' s 10-Year Current Ratio Range
Min: 1.2   Max: 2.69
Current: 2.61

1.2
2.69
Quick Ratio 2.24
JNJ's Quick Ratio is ranked higher than
76% of the 890 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. JNJ: 2.24 )
JNJ' s 10-Year Quick Ratio Range
Min: 0.94   Max: 2.37
Current: 2.24

0.94
2.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.60
JNJ's Dividend Yield is ranked higher than
100% of the 518 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. JNJ: 2.60 )
JNJ' s 10-Year Dividend Yield Range
Min: 1.64   Max: 3.84
Current: 2.6

1.64
3.84
Dividend Payout 0.45
JNJ's Dividend Payout is ranked higher than
95% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. JNJ: 0.45 )
JNJ' s 10-Year Dividend Payout Range
Min: 0.29   Max: 7.22
Current: 0.45

0.29
7.22
Dividend growth (3y) 7.10
JNJ's Dividend growth (3y) is ranked higher than
82% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. JNJ: 7.10 )
JNJ' s 10-Year Dividend growth (3y) Range
Min: 7.1   Max: 17.1
Current: 7.1

7.1
17.1
Yield on cost (5-Year) 3.72
JNJ's Yield on cost (5-Year) is ranked higher than
100% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. JNJ: 3.72 )
JNJ' s 10-Year Yield on cost (5-Year) Range
Min: 2.34   Max: 5.49
Current: 3.72

2.34
5.49
Share Buyback Rate -1.00
JNJ's Share Buyback Rate is ranked higher than
76% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. JNJ: -1.00 )
JNJ' s 10-Year Share Buyback Rate Range
Min: 2   Max: -3.9
Current: -1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.60
JNJ's Price/Tangible Book is ranked higher than
60% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. JNJ: 10.60 )
JNJ' s 10-Year Price/Tangible Book Range
Min: 6.25   Max: 38.85
Current: 10.6

6.25
38.85
Price/DCF (Projected) 1.64
JNJ's Price/DCF (Projected) is ranked higher than
90% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.00 vs. JNJ: 1.64 )
JNJ' s 10-Year Price/DCF (Projected) Range
Min: 0.87   Max: 3.6
Current: 1.64

0.87
3.6
Price/Median PS Value 1.30
JNJ's Price/Median PS Value is ranked higher than
72% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. JNJ: 1.30 )
JNJ' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.88
Current: 1.3

0.7
1.88
Price/Graham Number 2.88
JNJ's Price/Graham Number is ranked higher than
80% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.77 vs. JNJ: 2.88 )
JNJ' s 10-Year Price/Graham Number Range
Min: 1.95   Max: 11.69
Current: 2.88

1.95
11.69
Earnings Yield (Greenblatt) 7.30
JNJ's Earnings Yield (Greenblatt) is ranked higher than
91% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. JNJ: 7.30 )
JNJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.3   Max: 11.9
Current: 7.3

6.3
11.9
Forward Rate of Return (Yacktman) 5.73
JNJ's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. JNJ: 5.73 )
JNJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 17.9
Current: 5.73

1
17.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT » details
Traded in other countries:JNJ.Germany, JNJB34.Brazil, JNJ.Mexico, JNJ.Argentina, JNJ.Chile, JNJ.Switzerland
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO for the treatment of hepatitis C; INTELENCE and PREZISTA, treatments for HIV/AIDS; CONCERTA extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION, for the treatment of schizophrenia in adults; RISPERDAL CONSTA, for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE, a treatment for multiple myeloma; ZYTIGA, a treatment for metastatic castration-resistant prostate cancer; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT, to stimulate red blood cell production; and XARELTO, an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may cause to pulmonary embolism (PE) in patients undergoing hip
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
test_app_3 Nov 28 2014 
test_app_3 Nov 28 2014 
test_app_2 Nov 28 2014 
test_app Nov 28 2014 
U.S. Stocks Attractive As Euro-Area Economy Slides Nov 26 2014 
Consolidated Edison Has Increased Dividends for 40 Years Nov 25 2014 
Buy & Hold – Boring and Outdated Way to Invest? Nov 24 2014 
Is Managing A Large Dividend Growth Stock Portfolio Time Consuming? Nov 24 2014 
Walmart Still Rules The Retail Roost Nov 21 2014 
Johnson & Johnson´s Cash is Indicating at Least a Hold Position Nov 17 2014 


More From Other Websites
Johnson & Johnson's Rezolsta Approved in the EU for HIV-1 Nov 27 2014
Spanx for Your Face Nov 26 2014
Health Care ETFs Healthy on a Global Basis, Too Nov 26 2014
Apple eyes holiday sales Nov 26 2014
Apple breaks $700 billion Nov 25 2014
It was another slow, low volume, lackluster trading session Nov 24 2014
Motley Fool: Pundits pandering your wealth away Nov 22 2014
JOHNSON & JOHNSON Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 21 2014
Market getting a little toppy: Pro Nov 21 2014
Is The US Stock Market Unhealthy? Nov 21 2014
Dow, S&P close at records; Intel up 4% Nov 20 2014
J&J Seeks FDA Approval for Schizophrenia Treatment Nov 20 2014
J&J demands $7.2 bln from Boston Scientific as trial begins Nov 20 2014
J&J Seeks Billions in Trial Over Decade-Old Guidant Bidding War Nov 20 2014
Johnson & Johnson Partners with Save the Children to Help Millions of Children over the Next Three... Nov 19 2014
Mallinckrodt Q4 Earnings Beat Views, But Outlook Hazy Nov 19 2014
The rise of the social entrepreneur Nov 19 2014
Mallinckrodt Earnings Beat But No New Guidance Nov 19 2014
Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate Nov 19 2014
J&J Said to Boost Bond Sale as Investors Chase AAA Debt Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK